Half-Year 2022 Financial and Clinical Trials Update

HY 2022: Good underlying business momentum for both divisions % CER Pharma Quarterly sales evolution 2021-2022 % CER Diagnostics Quarterly sales evolution 2021-2022 Roche +55% +55% +48% +55% +45% +45% +35% +35% +31% +24% +25% +25% +17% +18% +14% +15% +15% +9% +4% +5% +6% +4% +5% +5% +11% 3% +10% +8% +8% +2% -5% -9% 0% +1% 0% -5% 0% -15% -11% -15% Q1 Q2 Q3 Q4 Q1 Q2 Q1 Q2 2021 vs. 2020 2022 vs. 2021 Q3 2021 vs. 2020 Q4 Q1 Q2 2022 vs. 2021 Pharma Pharma excl. Ronapreve -Diagnostics -Diagnostics Base business Growth rates at CER (Constant Exchange Rates) 10 10

View entire presentation